BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company aims to complement its core focus, nanosized antibody (“NanoAb”) pipeline development, with a comprehensive CDMO (contract development and manufacturing organization) offering. “With significant experience including developing its previous flu vaccine candidate, BiondVax intends to share its expertise, human resources and facilities with pharma companies to develop and manufacture their drug candidates for preclinical use as well as clinical testing,” a recent article reads. “BiondVax’s CDMO services cover aseptic fill and finish, upstream and downstream process development, as well as analytical model development, among others. In addition, the company also offers comprehensive CDMO services geared toward supporting pilot, clinical and process development stages, alternative protein food tech, pharmaceutical and biotech companies. The offering is intended to generate additional revenues for BiondVax and is made possible by the company’s growing assets ranging from GMP-ready production clean rooms to a 250mL Ambr(R) Fermentor and 2L and 5L fermentors for upstream process optimization. The company also offers Water for Injection (‘WFI’), 30L and 300L fermentors for upstream GMP production in addition to analytic tools, media and buffer preparation.”
To view the full article, visit https://ibn.fm/llVdr
About BiondVax Pharmaceuticals Ltd.
BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork